ImaginAb announces a new supply agreement with Invicro to offer clinical doses of ImaginAb’s CD8 investigational ImmunoPET imaging agent (zirconium Zr 89 crefmirlimab berdoxam) for Immuno-Oncology (I-O) preclinical research and clinical trials.

On May 12, 2022 ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), reported an agreement with Invicro LLC, a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to supply clinical doses of ImaginAb’s investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) for use in clinical trials as part of Invicro’s global core lab imaging service (Press release, Immudex, MAY 12, 2022, View Source [SID1234614372]). The agreement also allows Invicro to produce zirconium Zr 89 crefmirlimab for its preclinical offerings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This offering is a response to the growth seen in I-O therapies and demand from pharmaceutical and biotech companies for advanced, non-invasive, whole-body imaging biomarkers. ImaginAb’s investigational CD8 ImmunoPET agent provides a number of potential benefits that may help inform early decision making through Phase I-IV I-O clinical trials.

"We are delighted with our agreement with Invicro and the operational benefits we hope it will bring to its customers," stated Ian Wilson, CEO of ImaginAb.

"Driven through discussions with pharma and biotech companies that currently license our technology, we believe this partnership will bring the best of both businesses together, to offer the potential benefits that our investigational CD8 ImmunoPET imaging agent may bring in understanding therapeutic efficacy and treatment outcomes in clinical trials more precisely and earlier."

This offering is intended to provide pharma and biotech customers the opportunity to receive clinical doses of ImaginAb’s investigational CD8 ImmunoPET agent directly from Invicro.

"Invicro’s vision to transform health care through advanced imaging technologies aligns with ImaginAb’s investigational CD8 technology and mission. We believe this agreement will offer deeper insights into immune biology and pharmacodynamics that will help advance the development of therapies within the I-O space." commented Dr. Matthew Silva, CEO of Invicro.